A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Century Therapeutics

Status: Enrolling

Conditions: Solid Tumor Malignancy; Hematological Malignancy

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT05768269

CNTY-LTFU-01

Details and patient eligibility

About

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.

Enrollment: 375 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
• Participants received at least one treatment with a cellular therapy product in an eligible index trial.
• Participant was withdrawn, early discontinued or completed an eligible index trial.
• Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Exclusion criteria

-This study has no exclusion criteria.

Trial design

375 participants in 1 patient group

Cellular Therapy

Description:

Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.

Treatment:

Other: No Intervention